Compare VIST & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIST | ALKS |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | Mexico | Ireland |
| Employees | 584 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.5B |
| IPO Year | N/A | 2012 |
| Metric | VIST | ALKS |
|---|---|---|
| Price | $64.66 | $54.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $81.33 | $43.43 |
| AVG Volume (30 Days) | 786.5K | ★ 2.4M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $20.93 | $24.26 |
| Revenue Next Year | $20.35 | $4.47 |
| P/E Ratio | $7.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.37 | $25.17 |
| 52 Week High | $81.44 | $53.69 |
| Indicator | VIST | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 86.31 |
| Support Level | $62.56 | $27.65 |
| Resistance Level | $77.59 | N/A |
| Average True Range (ATR) | 2.76 | 1.97 |
| MACD | -0.94 | 0.76 |
| Stochastic Oscillator | 12.03 | 89.37 |
Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company has operations in Argentina and Mexico. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, it operates in Argentina and Mexico. Product-wise, the firm generates the majority of its revenue from crude oil sales, natural gas sales, and LPG sales.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.